top of page
Search Results

433 items found for "Cancer Research UK"

Programs (1)

  • GPCRs in Pharmacology

    Whether you are a healthcare professional, researcher, or student in the life sciences, this course will

View All

Posts (222)

  • Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares

    August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Cancer Research UK , a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own

  • Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...

    July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials " HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 22 July 2022 – Sosei Research UK , the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares ’ cancer immunotherapy drug candidate into a first-in-human trial.

  • The expression and clinical significance of GPR39 in colon cancer

    September 2022 " Background: Colorectal cancer is the third most common cancer and requires more prognostic The clinical significance of GPR39 in colon cancer has never been reported. Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues by retrieving TCGA data and detected the expression of GPR39 in colon cancers with qPCR and immunohistochemistry

View All

Other Pages (209)

  • Chemokine Physiology in Cancer

    < GPCR News < GPCRs in Oncology and Immunology Chemokine Physiology in Cancer Published date November In cancer, chemokines play paradoxical roles in both the directed emigration of metastatic, receptor-expressing cancer cells out of the tumor as well as immigration of tumor infiltrating immune cells that culminate therapies in cancer. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

  • Biochemical pharmacology of adenylyl cyclases in cancer

    Published date October 1, 2024 Abstract "Globally, despite extensive research and pharmacological advancement , cancer remains one of the most common causes of mortality. The expression patterns of ACs in numerous cancers are discussed. , G protein , GPCR , Hallmarks of Cancer , cAMP signaling . Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

  • Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer

    Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto

View All